Comparative effectiveness of bivalent BA.4-5 and BA.1 mRNA booster vaccines among adults aged ≥50 years in Nordic countries: nationwide cohort study.

Niklas Worm AnderssonEmilia Myrup ThiessonUlrike BaumNicklas PihlströmJostein StarrfeltKristýna FaksováEero PoukkaHinta MeijerinkRickard LjungAnders Hviid

Published in: BMJ (Clinical research ed.) (2023)

Vaccination with bivalent BA.4-5 or BA.1 mRNA booster vaccines as a fourth dose was associated with reduced rates of covid-19 related hospital admission and death among adults aged ≥50 years. The protection afforded by the bivalent BA.4-5 and BA.1 boosters did not differ significantly when directly compared, and any potential difference would most likely be very small in absolute numbers.

Keyphrases

sars cov
coronavirus disease
emergency department
healthcare
risk assessment
binding protein
climate change
human health